36.1% of patients on new Wegovy (NOVOB DC) weight-loss pill have no prior experience on a GLP-1 drug, new study finds; Among patients on new Wegovy pill, 21.1% switched from injectable wegovy, 15.8% switched from injectable zepbound
Importance
Level 1
#NOVO NORDISK A/S#NOVOB.DC#EU SESSION#US SESSION#EUROPEAN EQUITIES